Kevin Koch, Ph.D., is the President and Chief Executive Officer at EDGEWISE THERAPEUTICS INC, a biopharmaceutical company focused on developing innovative treatments for severe, rare neuromuscular and cardiac disorders. With a robust background in pharmaceutical research and development, Dr. Koch brings extensive experience and leadership to his role at Edgewise. He earned his Ph.D. in Chemistry from the University of California, Berkeley, and has since built an impressive career spanning over three decades. Prior to joining Edgewise Therapeutics, Dr. Koch held several key positions at major pharmaceutical companies, including serving as the Chief Scientific Officer at Array BioPharma, where he played a pivotal role in advancing the company's pipeline and forging strategic partnerships. His leadership was instrumental in the development and approval of several novel therapies, showcasing his ability to translate scientific innovation into tangible patient benefits. Dr. Koch's expertise in drug discovery and development, combined with his strategic vision, has been crucial in steering Edgewise Therapeutics towards its mission of addressing unmet medical needs in neuromuscular and cardiac diseases. As President and CEO of Edgewise Therapeutics, Dr. Koch is responsible for overseeing the company's overall strategy and operations. Under his guidance, Edgewise has made significant strides in advancing its clinical programs, particularly in the development of muscle-directed therapies. His commitment to scientific excellence and patient-centric innovation continues to drive the company forward, positioning Edgewise as a leader in the field of rare disease therapeutics. Dr. Koch's leadership is not only defined by his scientific acumen but also by his dedication to improving the lives of patients affected by severe neuromuscular and cardiac conditions.